Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700028315

Trial Profile

Clinical Trials Insight: 700028315

Phase of Trial: Phase I

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs THR 317 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors BioInvent International; ThromboGenics
  • Most Recent Events

    • 19 Nov 2009 Results were presented at 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009).
    • 03 Jun 2008 Status changed to completed, reported in a ThromboGenics media release.
    • 03 Jun 2008 Positive tolerability results announced in a Thrombogenics media release. Primary endpoints met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top